News about 'TB Treatment'

17 Feb 2016
Tuberculosis continues to become more resistant to existing drug regimens resulting in a need for constant innovation on the part of drug researchers. In an article published by Medicalxpress.com which can be found here , researchers are reported to have found a chemical alteration that makes...
19 Feb 2015
TB Alliance announced that its compound TBA-354 has started Phase I clinical trials. This announcement is particularly exciting given that TBA-354 is the first TB drug to enter Phase I trials since 2009. TBA-354 is a next generation compound in the nitroimidazole class, which also includes...
7 Jan 2015
Researchers at the Center for Tuberculosis Research located at Johns Hopkins University School of Medicine have shown that heart medication, verapamil administered in combination with bedaquline lowers the toxicity of the TB drug without altering its efficacy. The paper, titled ‘ Verapamil...
8 Sep 2014
Moxifloxacin Results of the Phase III REMoxTB clinical trial were published in the New England Journal of Medicine on September 7th, 2014. REMox or Rapid Evaluation of Moxifloxacin in Tuberculosis (REMoxTB) was a trial designed to determine whether replacement of either ethambutol or isoniazid with...
20 Jul 2014
Scientists at Janssen Pharmaceutica have characterized a novel resistance mechanism to Bedaquiline (BDQ), a second line antibiotic for the treatment of MDR-TB. The research study , published in Plos One , showed that tuberculosis resisted BDQ treatment by developing a mechanism to pump the drug out...
29 Apr 2014
The European Commission has approved Delaminid (Deltyba™) for use in patients suffering from MDR-TB. Delamanid was developed by Otsuka Pharmaceutical Co., Ltd., a Japanese pharmaceutical company dedicated to drug discovery for tuberculosis. The press release from Otsuka can be found here Related...
22 Apr 2014
The drug SQ109, developed by Sequella for the treatment of tuberculosis, blocks key biochemical pathways in bacteria, fungi, and parasites. The multiple targets of SQ109 have been determined by researchers at the University of Illinois Urbana-Champaign. The researchers also created analogs of SQ109...
22 Apr 2014
TB Alliance has announced that it will conduct a landmark Phase 3 clinical trial aimed at shortening the treatment of drug sensitive and MDR-TB. The trial known as STAND (Shortening Treatments by Advancing Novel Drugs) will test the PaMZ drug regimen composed of two drug candidates not yet approved...
11 Mar 2014
Vadim Makarov et. al. Towards a new combination therapy for tuberculosis with next generation benzothiazinones . EMBO Molecular Medicine. 2014. March 1; 6(3). doi: 10.1002/emmm.201303575 A new antibiotic, labeled ‘PBTZ169’, has been shown to be effective against drug sensitive and MDR-tuberculosis...
29 Jul 2013
Source: Bloomberg http://www.bloomberg.com/news/2013-07-26/otsuka-s-drug-resistant-tb-treatment-fails-to-win-ema-nod.html Otsuka’s Drug-Resistant TB Treatment Fails to Win EMA Nod Otsuka Holdings Co. (4578) failed to win the backing of a European Medicines Agency panel for the Delamanid medicine...
12 Jun 2013
From the Stop TB Parntership News: The World Health Organization (WHO) has issued interim guidance on the use of bedaquiline, a new tuberculosis drug, for the treatment of multidrug-resistant tuberculosis (MDR-TB). Bedaquiline was granted accelerated approval by the United States Food and Drug...
15 Apr 2013
MSF Scientific Day 2013 will be streamed live online from the Royal Society of Medicine, London, UK, from 09.00am – 06.00pm (GMT+1) on 10 th May 2013 http://www.msf.org.uk/Scientific_Day.aspx MSF Scientific Day is a unique opportunity to showcase medical and scientific research carried out in MSF...
26 Nov 2012
The week of November 12th was exciting with the 43rd Union World Conference, the WGND Annual Meeting (will be posting presentations soon), and the Stop TB Coordinating Board Meeting. Below are some news highlights and a listing of webcasts of interesting and presentations relevant for TB drug...
3 Sep 2012
Anna K. Coussensa, Robert J. Wilkinson, Yasmeen Hanifa, Vladyslav Nikolayevskyy, Paul T. Elkington, Kamrul Islam, Peter M. Timms, Timothy R. Venton, Graham H. Bothamley, Geoffrey E. Packe, Mathina Darmalingam, Robert N. Davidson, Heather J. Milburn, Lucy V. Baker, Richard D. Barker, Charles A. Mein...
8 Mar 2012
At the 19th Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, results on the Thibela TB preventative therapy trial in South Africa gold miners was presented with mixed outcomes. On one hand, the number of cases in miners in the experimental group who screened negative for...

Pages